In a recent transaction, Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences Corp (NYSE:EW), sold shares of the company's stock, according to a new SEC filing. The executive disposed of 857 shares at a price range of $92.34, totaling approximately $79,135.
The sale was executed under a Rule 10b5-1 trading plan, which was previously adopted on December 11, 2023. This plan allows company insiders to set up a predetermined schedule for buying and selling shares at a time when they are not in possession of material non-public information, to avoid accusations of insider trading.
On the same day, Lippis also acquired 857 shares of common stock at $36.75 per share, amounting to $31,494. This transaction reflects the quarterly acquisition of shares under the issuer's Employee Stock Purchase Plan, as noted in the remarks section of the filing.
Following the sale, Lippis's ownership in Edwards Lifesciences Corp stands at 17,487.7443 shares of common stock. The transactions were reported to the SEC in a Form 4 filing on April 9, 2024.
Investors often monitor insider buying and selling as it can provide insights into a company's internal views and potential future performance. However, such transactions do not necessarily indicate future price movements and should be considered alongside other factors.
Edwards Lifesciences Corp, based in Irvine, California, specializes in orthopedic, prosthetic, and surgical appliances and supplies. The company is incorporated in Delaware and has a fiscal year end on December 31.
InvestingPro Insights
Edwards Lifesciences Corp (NYSE:EW), a leader in medical innovations, has been drawing attention with its robust financial performance and market activity. According to InvestingPro data, the company boasts a market capitalization of $55.91B USD, reflecting its significant presence in the healthcare sector. Investors are closely watching the company's P/E ratio, which stands at 39.87, indicating a premium valuation compared to the industry average. This high earnings multiple is further emphasized by an adjusted P/E ratio for the last twelve months as of Q4 2023, which is slightly lower at 35.41, suggesting a slight adjustment in valuation over the recent period.
Edwards Lifesciences has demonstrated a solid revenue growth of 11.56% over the last twelve months as of Q4 2023, underscoring its ability to expand its financial base in a competitive market. This growth trajectory is complemented by a gross profit margin of 77.02%, highlighting the company's efficiency in managing its cost of goods sold and maintaining profitability.
One of the InvestingPro Tips for Edwards Lifesciences is that the company's cash flows can sufficiently cover interest payments, which is a reassuring sign for investors concerned about the company's financial health and its ability to meet its debt obligations. Additionally, Edwards Lifesciences operates with a moderate level of debt, which is an important consideration for investors looking for sustainable financial practices.
For those interested in further insights and tips, including whether Edwards Lifesciences is trading near its 52-week high or if analysts predict the company will be profitable this year, there are 15 additional InvestingPro Tips available at https://www.investing.com/pro/EW. To gain access to these valuable tips, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.